Moderate riskFDA DrugClass II

Brandywine theophylline 200 mg tablets recalled over stability testing

Brandywine Pharmaceuticals is recalling one lot of theophylline extended-release tablets, 200 mg, in 100-count bottles. The FDA classified it as Class II after a gap was found in ongoing stability testing done at a third-party lab. No injuries have been reported.

From the FDA notice · Read the official notice ↗

What to do

  1. Check the bottle for NDC 71321-501-10, lot 405620, and expiry 03/31/2028.
  2. Do not stop taking your prescribed medicine without first talking to your doctor or pharmacist.
  3. Contact your pharmacy or Brandywine Pharmaceuticals for guidance on replacement, since no remedy has been specified.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.
Sold in
Nationwide
Made for
Adults (under 0 months)

This recall covers 2 products — see all of them.

Details

Units affected
1,332 100-count bottles
Illnesses reported
None reported
Manufactured in
600 W Strasburg Rd, West Chester, Pennsylvania, United States
Classification
Class II
Recall number
D-0111-2027

In the FDA's words

Description
Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10. CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory Lot: 405620, Expiry: 03/31/2028. Distribution: Nationwide within U.S Affected quantity: 1,332 100-count bottles
Hazard
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

2 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

OtherDrugsSold nationwideMore from FDA Drug